Black Rock Inc. Lyra Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 151,919 shares of LYRA stock, worth $42,537. This represents 0.0% of its overall portfolio holdings.

Number of Shares

151,919

Previous 110,797 37.11%

Holding current value

$42,537

Previous $580,000 62.76%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$4.55 - $6.53 $187,105 - $268,526	41,122 Added 37.11%	151,919 $944,000
Q4 2023 Feb 13, 2024	BUY	$2.82 - $5.24 $178,548 - $331,770	63,315 Added 133.35%	110,797 $580,000
Q3 2023 Nov 13, 2023	SELL	$2.95 - $4.8 $3,339 - $5,433	-1,132 Reduced 2.33%	47,482 $185,000
Q2 2023 Aug 11, 2023	BUY	$1.98 - $4.33 $14,323 - $31,323	7,234 Added 17.48%	48,614 $199,000
Q1 2023 May 12, 2023	BUY	$1.95 - $3.09 $2,468 - $3,911	1,266 Added 3.16%	41,380 $83,000

Q4 2022 Feb 13, 2023	BUY	$2.44 - $4.92 $2,681 - $5,407	1,099 Added 2.82%	40,114 $125,000
Q3 2022 Nov 14, 2022	SELL	$5.33 - $6.6 $13,682 - $16,942	-2,567 Reduced 6.17%	39,015 $196,000
Q2 2022 Aug 12, 2022	BUY	$4.12 - $7.51 $93,013 - $169,545	22,576 Added 118.78%	41,582 $235,000
Q1 2022 May 12, 2022	BUY	$3.5 - $5.36 $2,565 - $3,928	733 Added 4.01%	19,006 $77,000
Q4 2021 Feb 10, 2022	BUY	$4.22 - $9.41 $1,920 - $4,281	455 Added 2.55%	18,273 $80,000
Q3 2021 Nov 09, 2021	SELL	$6.06 - $9.43 $13,950 - $21,707	-2,302 Reduced 11.44%	17,818 $163,000
Q2 2021 Aug 11, 2021	BUY	$6.91 - $12.59 $139,029 - $253,310	20,120 New	20,120 $161,000

Others Institutions Holding LYRA

# of Institutions

Shares Held

44.4M

Call Options Held

300K

Put Options Held

1.3K

View Full List

About Lyra Therapeutics, Inc.

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $8.91M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

More about LYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account